BioMarin Pharmaceuticals
BMRN
Market cap $13.2B

69.51 USD

+1.35

1.98%

At close Oct 4, 4:00 PM EDT

After hours

69.51

+0.00

0%

1 day

1.98%

5 days

-1.52%

1 month

-17.33%

3 months

-15.93%

6 months

-20.36%

Year to date

-29.11%

1 year

-21.11%

5 years

5.57%

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,728 funds

0

Analysts bullish %

of 28 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

1% more funds holding

Funds holding: 540 [Q1] → 548 (+8) [Q2]

10% more first-time investments, than exits

New positions opened: 90 | Existing positions closed: 82

0% more funds holding in top 10

Funds holding in top 10: 6 [Q1] → 6 (+0) [Q2]

0.43% less ownership

Funds ownership: 97.48% [Q1] → 97.04% (-0.43%) [Q2]

1% less repeat investments, than reductions

Existing positions increased: 189 | Existing positions reduced: 190

8% less call options, than puts

Call options by funds: $153M | Put options by funds: $166M

6% less capital invested

Capital invested by funds: $16.1B [Q1] → $15.2B (-$895M) [Q2]

See Fund Rankings

Research analyst outlook

28 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$78

12%

upside

Avg. target

$102

46%

upside

High target

$122

76%

upside

28 analyst ratings

19 positive

68%

9 neutral

32%

0 negative

0%

RBC Capital Luca Issi 24% 1-year accuracy 12 / 51 met price target	15%upside $80	Sector Perform Maintained	4 Oct 2024
Barclays Gena Wang 35% 1-year accuracy 9 / 26 met price target	24%upside $86	Overweight Maintained	4 Oct 2024
Scotiabank George Farmer 12% 1-year accuracy 2 / 17 met price target	12%upside $78	Sector Perform Maintained	17 Sept 2024
Truist Securities Joon Lee 64% 1-year accuracy 28 / 44 met price target	29%upside $90	Buy Maintained	17 Sept 2024
Wells Fargo Mohit Bansal 48% 1-year accuracy 10 / 21 met price target	29%upside $90	Overweight Maintained	17 Sept 2024

See Analyst Rankings

Financial journalist opinion

Based on 9 articles about BMRN published over the past 30 days

3 Oversold Stocks with Big RSI Rebound Potential

Everybody loves finding a bargain or getting a good deal, and it's no different when it comes to stocks. One of the most popular technical indicators for helping investors find these is the Relative Strength Index (RSI).

3 Oversold Stocks with Big RSI Rebound Potential

Zacks Investment Research

3 Reasons Why Growth Investors Shouldn't Overlook BioMarin (BMRN)

BioMarin (BMRN) is well positioned to outperform the market, as it exhibits above-average growth in financials.

3 Reasons Why Growth Investors Shouldn't Overlook BioMarin (BMRN)

Zacks Investment Research

BMRN or MYGN: Which Is the Better Value Stock Right Now?

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with BioMarin Pharmaceutical (BMRN) and Myriad Genetics (MYGN). But which of these two companies is the best option for those looking for undervalued stocks?

BMRN or MYGN: Which Is the Better Value Stock Right Now?

Zacks Investment Research

Down -22.94% in 4 Weeks, Here's Why You Should You Buy the Dip in BioMarin (BMRN)

BioMarin (BMRN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Down -22.94% in 4 Weeks, Here's Why You Should You Buy the Dip in BioMarin (BMRN)

Zacks Investment Research

Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term

BioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman Sachs Analyst Remains Bullish

Last week, Ascendis Pharma A/S ASND released topline data on Monday from a trial that included 84 children with achondroplasia, a genetic disorder that causes dwarfism and disproportionate short stature.

BioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman Sachs Analyst Remains Bullish

BioMarin to Present Data Underscoring Sustained Positive Impact of VOXZOGO® (vosoritide) on Health-Related Quality of Life, Growth and Maintenance of Bone Strength in Children with Achondroplasia at 2024 International Skeletal Dysplasia Society Meeting

Results from Ongoing CANOPY Clinical Program for VOXZOGO Showcase Impact of C-Type Natriuretic Peptide (CNP) as Master Regulator of Growth-Related Development Across Multiple Genetic Skeletal Conditions New Data Highlight Meaningful Improvements in Health-Related Quality of Life for Children with Achondroplasia Investigator-Led Study Shows Significant Increases in Bone Length While Maintaining Bone Strength in Children with Achondroplasia Investigator-Led Study Observes Sustained Growth Gains in Children with Hypochondroplasia, Noonan Syndrome and Genetic Variants Associated with Idiopathic Short Stature SAN RAFAEL, Calif. , Sept. 18, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that positive data from the CANOPY clinical program evaluating VOXZOGO® (vosoritide) in children with achondroplasia and other genetic skeletal conditions will be presented at the 16th International Skeletal Dysplasia Society meeting (ISDS) in Madrid, Sept.

BioMarin to Present Data Underscoring Sustained Positive Impact of VOXZOGO® (vosoritide) on Health-Related Quality of Life, Growth and Maintenance of Bone Strength in Children with Achondroplasia at 2024 International Skeletal Dysplasia Society Meeting

Ascendis Challenges BioMarin, But Market Response Seems Excessive

Ascendis' TransCon CNP showed similar efficacy to BioMarin's Voxzogo, but offers once-weekly dosing, potentially improving patient adherence. The achondroplasia market is significant, with potential annual revenues approaching $1 billion, but competition may impact market share. Ascendis faces financial challenges, including a cash runway of approximately 15 months and a current ratio below 1.0.

Ascendis Challenges BioMarin, But Market Response Seems Excessive

Zacks Investment Research

Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock

Zacks Investment Research

BioMarin Posts '27 Biz View, Outlines Growth Plans for Next 10 Years

BMRN divulges ambitious plans for business growth over the next 10 years. It expects yearly sales to grow at a mid-teen rate through 2034.

BioMarin Posts '27 Biz View, Outlines Growth Plans for Next 10 Years

See News Rankings

Charts implemented using Lightweight Charts™